Correction to: Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study

PURPOSE Sunitinib offers improved efficacy for patients with metastatic renal cell carcinoma (mRCC). To provide better disease management in the Middle East, we studied its use in mRCC in real-life practice in this region. MATERIAL AND METHODS Patients diagnosed with mRCC and started on sunitinib between 2006 and 2016 from 10 centers in Africa and the Middle East region were studied in this regional, multicenter, observational, retrospective trial to obtain routine clinical practice data on the usage patterns and outcomes of sunitinib in mRCC in real-life practice. RESULTS A total of 289 patients were enrolled. Median age at diagnosis was 58.7 years. The patient characteristics were as follows: 73.6% of patients were males; 85.8% had clear-cell renal cell carcinoma (RCC); 97.5% had unilateral RCC; 66.3% had metastatic disease at initial diagnosis; 56.3% received previous treatment for RCC, among which 98.7% had undergone surgery; and 15.2% and 31.4% were classified in the favorable and poor-risk groups (expanded Memorial Sloan Kettering Cancer Center criteria), respectively. On treatment initiation, the mean total sunitinib dose was 48.1 mg, and 87.6% of patients were started on a sunitinib dose of 50 mg. The mean duration of sunitinib treatment was 9.6 months. Overall response rate was 20.8%, with a median duration of 8.2 months. Median time to progression was 5.7 months. Median follow-up time was 7.8 months. By months 12 and 24, 34.3% and 11.4% of patients, respectively, were still alive. Seventy-six patients (60.9%) experienced 314 adverse events. Twenty-three patients (8.0%) experienced 28 serious adverse events. Overall, 83 patients (28.7%) discontinued their sunitinib treatment. CONCLUSION The results are indicative of the general treatment outcomes of patients with mRCC in the Middle East using sunitinib in routine clinical practice. Reported adverse events are similar to those described in the literature but at lower frequencies.

Download Full-text

Observational study evaluating resource utilization among metastatic renal cell carcinoma patients treated with mTOR inhibitors in the outpatient community-based setting.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.e15027 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. e15027-e15027

Author(s):

C. Chen ◽

S. K. Gruschkus ◽

Z. Liu ◽

N. J. Vogelzang ◽

M. T. Forsyth ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Observational Study ◽

Cell Carcinoma ◽

Resource Utilization ◽

Metastatic Renal Cell Carcinoma ◽

Renal Cell ◽

Mtor Inhibitors ◽

Community Based

Download Full-text

Insights into the epidemiology of renal cell carcinoma in North Africa and the Middle East

Journal de la faculté de médecine d'Oran ◽

10.51782/jfmo.v1i1.24 ◽

2017 ◽

Vol 1 (2) ◽

Author(s):

Marwan Ghosn ◽

Mohammed Jaloudi ◽

Blaha Larbaoui ◽

Adib Salim ◽

Lydia Dreosti

Keyword(s):

Renal Cell Carcinoma ◽

Middle East ◽

Cell Carcinoma ◽

North Africa ◽

Survival Data ◽

Renal Cell ◽

Descriptive Study ◽

Accurate Data ◽

Targeted Agents ◽

The Usa

Purpose - Recent improvements in the treatment of renal cell carcinoma (RCC), with the introduction of targeted agents, have increased the need of accurate data on its epidemiology. This descriptive study was designed to collate comprehensiveinformation on RCC epidemiology from North Africa and the Middle East, which could provide the basis for further research.Methods - A network of reference oncologists in North Africa and the Middle East were invited to share all available national and regional information on RCC epidemiology, captured in a comprehensive questionnaire. No statistical analysis wasplanned as the intention was to conduct a purely descriptive study.Results - The results reported that the incidence of RCC within the region is in the range of 0.9–2.35/100,000 for men (with Lebanon as an exception at 4.3/100,000 for men) and 0.5– 1.7/100,000 for women, which is considerably lower than in Europe and the USA. No mortality or survival data are available. The age at diagnosis (mean <60 years) is lower than in Western countries and a high proportion of patients in North Africa and the Middle East (21?45%) have metastatic disease at diagnosis.Conclusions - The information presented here provides a more complete and current picture of RCC in North Africa and the Middle East; however, there are still gaps in the data. Further research is needed to allow planning of treatmentstrategies and resource allocation.

Download Full-text